SOMERSET, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (the “Company”) (Nasdaq: CCLD, CCLDO), a leading provider of healthcare technology and AI-powered revenue cycle management (RCM) solutions, today announced the expanded adoption of its services by Alpine Ear, Nose & Throat PC, a premier otolaryngology group based in Colorado. Following a successful RCM engagement, Alpine ENT has now implemented CareCloud FrontDesk Assist—a comprehensive front-office... Read more
First Logica-identified candidate marks a progression-based milestone in ongoing partnership with Pioneering Medicines, Flagship Pioneering’s in-house drug development unit WILMINGTON, Mass. & CAMBRIDGE, Mass. / Mar 25, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications... Read more
VERDI's personalized vaccines have demonstrated safety and efficacy in cancer patients SAN JOSE, Calif., March 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a letter of intent with VERDI Solutions, GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients.
VERDI Solutions, headquartered... Read more
Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan
Tumor response models for novel compounds represent true drug discovery using Predictive's active machine learning platform PITTSBURGH, March 25, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has successfully developed predictive... Read more
Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that it has entered into a non-binding letter of intent dated March 18, 2025, (the "LOI") to acquire all of the issued and outstanding shares (the "Transaction") of Monjin Interviews Private Limited ("Monjin"), a corporation formed under the laws of India. The Transaction is an arm's length transaction.
About Monjin - https://www.monjin.c... Read more
Toronto, Ontario – TheNewswire - March 24, 2025 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce the release of a whitepaper comparing the performance of the VMS+™4.0 advanced Automated Radiological Image Processing Software/System to the previous basic model, VMS+ 3.0.
This latest advancement of Ventripoint’s proprietary technology, VMS+ 4.0, which recently received U.S. FDA 510(k) clearance, delivers a... Read more
The latest Invenia ABUS is designed to deliver optimal outcomes with its innovative, patient-friendly, and efficient AI-driven technology
Invenia ABUS Premium features new integrated Verisound AI and AI Assistant, which ensure faster and reproducible scanning and reading with extraordinary image quality
The non-invasive ultrasound technology, equipped with a novel Reverse Curve transducer and separate acquisition and reading capabilities, is built to enhance patient... Read more
Adoption allows ICON to take full advantage of the Medidata “Data Experience,” leveraging AI to unify data sources, standardize outputs, and reduce reconciliation efforts NEW YORK / Mar 20, 2025 / Business Wire / Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization (CRO) powered by healthcare intelligence, will... Read more
SUNNYVALE, Calif. and SECAUCUS, N.J., March 18, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a collaboration with Google Cloud to streamline Quest's data management, improve data analytics, and personalize the experiences Quest delivers to patients, providers and other customers.
To do so, Quest Diagnostics will use Google Cloud's data analytics and generative AI (gen AI) technologies, including Google... Read more
Collaboration aims to make portable MRI faster, smarter, and more accessible worldwide. GUILFORD, Conn. / Mar 17, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced a strategic collaboration with NVIDIA. This collaboration leverages NVIDIA AI expertise and... Read more
FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strategic collaboration aimed at identifying and evaluating biopharmaceutical compounds using artificial intelligence (AI) for potential acquisition or licensing by Fortress.
Partex will deploy its proprietary AI-based drug discovery and development technology platform, which delivers... Read more
TORONTO and DALLAS, March 17, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today announced the submission of a Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for the Company's next-generation Perimeter B-Series OCT system, which combines proprietary artificial intelligence ("AI") technology with optical coherence... Read more
DeepView® System outperforms burn physicians in identifying non-healing tissue
Landmark Burn Validation Study, one of the largest in U.S. history, confirms DeepView’s performance
Spectral AI plans FDA submission by mid-2025, targeting De Novo Clearance and rapid commercialization to transform burn care DALLAS, March 17, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, that... Read more
GeneDx's Multiscore tool to be showcased at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting GAITHERSBURG, Md. / Mar 13, 2025 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Multiscore, an advanced AI-powered decision support tool designed to revolutionize genetic analysis by improving diagnostic efficiency, streamlining workflows, and enhancing clinical insights.... Read more
MeiraGTx to receive $200 million in upfront cash consideration
MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen to fund 100% of the development of AAV-GAD for Parkinson’s disease through to commercialization, as well as other potential pipeline products
MeiraGTx will enter into clinical and commercial supply agreements with Hologen Neuro AI Ltd to manufacture AAV-GAD and other locally... Read more
VANCOUVER, British Columbia, March 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, announced today that the company has received the first synthesized batch of AI-generated ATR inhibitor compounds developed in collaboration with Variational AI.
This milestone marks a significant step forward in Rakovina’s mission... Read more
Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing network CHICAGO / Mar 11, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies.
Deep... Read more
Harnessing AI-Powered Scent Digitization for Smarter, Safer, and More Sustainable Factories With this collaboration, Ainos takes a major step in its mission to digitize scent - expanding its expertise from healthcare applications to industrial automation. AI Nose, originally developed for volatile organic compound (VOC) detection in medical diagnostics, is now expanding to smart factories. By unlocking insights from invisible chemical patterns in the air, AI Nose has... Read more
WEXFORD, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced its strategic partnership with COEPTIS’ NexGenAI Affiliates Network “NexGen” and NUBURU, Inc. “NUBURU” (NYSE: BURU), a leading innovator in high-power blue laser technology. This collaboration is a pivotal component of COEPTIS’ strategic position in technology... Read more
A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementia Calgary, Alberta--(Newsfile Corp. - March 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, including vascular dementia, announces its collaboration with... Read more
TEL AVIV, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the successful closing of its previously announced acquisition of 100% of the business activity of DeepSolar, an AI-driven solar analytics platform, from BladeRanger Ltd, a public company registered under the laws of the State of Israel,... Read more
Strategic collaboration harnesses GATC’s proprietary Artificial Intelligence-powered, validated Multiomics Advanced Technology™ platform to rapidly optimize and derisk drug discovery and development, thereby accelerating and economizing the traditional drug development process.
Lisata’s investigational product, certepetide, to be the subject of a comprehensive AI-analysis to determine optimum disease targets and development strategies.
GATC to leverage Lisata’s... Read more
POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer's disease (AD) and other causes of dementia. With Alzheimer's accounting for approximately 60-80% of all dementia cases, alongside other conditions such as vascular disease, Lewy body disease,... Read more
WILMINGTON, Del., March 03, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a leading AI-powered physician enablement platform, today announced it has partnered with Google Cloud to integrate Vertex AI Search into its flagship technology, Counterpart Assistant. This innovation gives providers on Counterpart Assistant a generative AI (gen AI) search experience across the breadth of a patient’s digital health record to provide contextualized insights,... Read more
SOUTH SAN FRANCISCO, Calif., March 3, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced a research collaboration with ATTMOS as part of its efforts to build a physics-based computational small molecule discovery platform that rapidly unlocks what are currently perceived as undruggable oncology targets.
The collaboration will integrate IDEAYA's... Read more
Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging trends in efficacy for REC-994 in cerebral cavernous malformations
Advanced three new clinical studies across oncology, rare disease, and recurrent C. diff infection with REC-1245, REC-4881, and REC-3964
Delivered milestones for partners including the first neuro-phenomap for Roche and Genentech and two milestones for Sanofi... Read more
VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, proudly reaffirms its strategic partnership with Variational AI. This announcement comes on the heels of Variational AI’s impressive $5.5 million oversubscribed financing round, led by Nimbus Synergies with participation from Flying Fish Ventures, Merck Global... Read more
AUSTIN, Texas / Feb 26, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with RIBOPRO, a pioneering technology provider specializing in mRNA and lipid nanoparticle (LNP) technologies. This collaboration seeks to revolutionize the discovery and development of therapeutic antibodies by integrating RIBOPRO’s advanced... Read more
VeroSource to support cutting edge Digital Twin technology on its VS Data-as-a-Service Platform, delivering real-time insights and advanced data visualization to optimize healthcare operations.
A Digital Twin is a virtual model of a healthcare system or facility that provides real-time insights for better decision-making. By simulating operations without disruption, this technology allows healthcare managers to optimize efficiency, reduce costs, and enhance patient care.
Key... Read more
At ECR 2025, DeepHealth will introduce new AI-powered radiology informatics and cancer screening solutions enabled by DeepHealth OS, its pioneering cloud-native operating system, to address clinical and operational challenges.
DeepHealth aims to bring to European customers its Diagnostic Suite™ to redefine the traditional Picture Archiving and Communication System (PACS) with a unified workspace tailored for modern radiology, and SmartMammo™, an AI-powered end-to-end... Read more
TORONTO, Feb. 25, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, announces its funded collaboration with the Ontario Brain Institute (OBI) to enhance the analysis of brain imaging and multi-modal data from Major Depressive Disorder (MDD) clinical research to achieve treatment separation in future clinical trials.
The collaboration,... Read more
DeepHealth’s cloud-native Diagnostic Suite™ will integrate TeraRecon’s SaaS-based advanced visualization capabilities, creating a unified AI-powered diagnostic workspace that enhances workflows and expands access to advanced diagnostic tools across diverse healthcare settings.
The collaboration will also integrate DeepHealth’s clinical AI solutions into TeraRecon’s AI ecosystem, augmenting its capabilities and expanding its impact in diagnostic imaging.
Both... Read more
SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial intelligence (AI)-enabled prognostic and predictive tests for advancing access to personalized medicine and empowering treatment decisions, announced that they have entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ’s AI technology... Read more
Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, before the open of the financial markets.
Recursion will host a (L)earnings Call on February 28, 2025 at 8:30 am ET / 6:30 am MT / 1:30 pm GMT. The company... Read more
In Q4-2024, HEALWELL's subsidiary, Khure Health ("Khure") helped physicians identify over 43,000 high-risk patients with its AI-Powered Physician Co-Pilots, across 8 clinical specialities harnessing 132 disease specific algorithms. This figure reflected a quarter over quarter sequential growth of 22% as compared to Q3-2024 and year-over-year growth of 500% as compared to Q4-2023.
HEALWELL has executed 4 new Master Services Agreements ("MSA") with new pharmaceutical partners... Read more
WEXFORD, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced an exciting strategic partnership with COEPTIS’ NexGenAI Affiliates Network and Arketyp Valu, a prominent developer within the open-source Verus Project, which has recently achieved a market capitalization exceeding $500 million. This collaboration aims to integrate... Read more
Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets
Incyte receives exclusive rights to develop and commercialize collaboration products WILMINGTON, Del. & BURLINGAME, Calif. / Feb 20, 2025 / Business Wire / Incyte (Nasdaq:INCY) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration... Read more
Collaboration reinforces Conduit’s commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug development
Sarborg delivers a prototype AI-product to Conduit’s Management team NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), is pleased to announce the completion of the initial milestones in Phase II... Read more
SALT LAKE CITY, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Altitude Lab, a biotech accelerator started by Recursion in Salt Lake City, today announced the launch of its pre-seed venture fund aimed at supporting early-stage biotechnology startups impacted by recent federal funding policy shifts. Together with Altitude Lab, Altitude Lab Fund intends to provide crucial capital, lab space, and mentorship to promising Small Business Innovation Research (SBIR) reviewed companies, further... Read more
DeepSolar brings new customer base in creation, including major utility-scale solar operators and independent power producers, while breaking into the residential solar market
The Company remains committed to advancing its drug delivery technologies while broadening its growth potential TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the... Read more
Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types
Creates significant business development opportunities with meaningful long-term commercial potential with large pharmaceutical companies PITTSBURGH, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today provided an update highlighting new successes... Read more
Vancouver, British Columbia--(Newsfile Corp. - February 13, 2025) - Kovo+ Holdings Inc. (formerly Kovo HealthTech Corporation) (TSXV: KOVO) ("Kovo" or the "Company") is pleased to announce that it has entered into a non-binding letter of intent (the "LOI") with Avonlea Ventures #2 Inc. ("AVI"), whereby the Company intends to acquire (the "Proposed Transaction") certain contractual assets of AVI, including the exclusive right to acquire, among other things: (i) all of the... Read more
VANCOUVER, BC, Feb. 13, 2025 /CNW/ - CareSpan Health, Inc. (TSXV: CSPN) (the "Company" or "CareSpan"), announces that it has entered into a binding definitive agreement among Medtech AI Inc. ("Medtech"), a company incorporated under the laws of Ontario, and 1001132953 Ontario Inc., a company existing under the laws of Ontario, (the "SubCo") effective as of February 11, 2025 (the "Definitive Agreement"), whereby CareSpan will acquire all the issued and outstanding common... Read more
The use of the DARWEN™ AI platform achieved time savings representing a 100-fold improvement as compared to traditional manual processes(1), demonstrating the opportunity to advance care and improve patient outcomes by leveraging cutting edge AI technology in clinical care. This study was conducted in collaboration with Princess Margaret Cancer Centre and is one of the world's first peer-reviewed studies to use an artificial intelligence platform to demonstrate... Read more
CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the filing of two new patent applications, covering groundbreaking developments in the treatment... Read more
Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, which will focus on developing personalized software dashboards to enhance efficiency, decision-making, and operational agility of its current and future portfolio NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”),... Read more
Landmark single-cell dataset of one billion cells will be used to train new AI models to advance researchers' understanding of cellular behavior and gene function REDWOOD CITY, Calif. , Feb. 6, 2025 /PRNewswire/ -- Today, the Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, an effort to generate an unprecedented one billion cell dataset to fuel rapid progress in AI model development in biology. CZI is embarking on this landmark initiative... Read more
VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, announces continued advancement of its AI-driven drug discovery program. Over the next four months, additional small-molecule drug candidates, designed in collaboration with Pharma Inventor Inc., will be synthesized and delivered for further evaluation.
The expanded... Read more
WILMINGTON, Del., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), an AI-powered physician enablement platform, today announced a strategic, multi-year agreement with Southern Illinois Healthcare (SIH), a regional leader in healthcare delivery and the largest health system in Southern Illinois. Counterpart is a subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”).
This partnership will enable SIH’s care teams... Read more
Inspira Technologies develops its innovative AI-powered HYLA technology with advanced blood testing capability, enabling continuous monitoring of tissue oxygenation and early hypoxia detection; Company expects to release preliminary clinical results for the sensor in the near future RA'ANANA, Israel, Feb. 5, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in breakthrough life-support technology,... Read more
